http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105523994-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-58 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-58 |
| filingDate | 2016-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105523994-B |
| titleOfInvention | Methanesulfonic acid Lome Tapai crystal form III |
| abstract | The present invention provides a kind of crystal form III of methanesulfonic acid Lome Tapai, the X x ray diffration pattern xs of the crystal form, which have, is included in 2 θ of the angle of diffraction：9.912 degree, 11.584 degree, 14.651 degree, 15.444 degree, 17.416 degree, 21.154 degree, 21.984 degree of diffraction maximum, 2 θ errors are ± 0.2 degree.The stable preparation process of the present invention is controllable, and the crystal form III that can adapt to, in industrialized production, obtain has good stability, and disclosure satisfy that the medicinal requirements of production and transport storage；Purity is higher, and impurity content is less, does not contain or the only residual solvent containing lower content, meets the limitation requirement in relation to medical product residual solvent as defined in National Pharmacopeia, thus the crystallization of the present invention can be used preferably as medicating active ingredients. |
| priorityDate | 2016-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.